Pancreatic Tumor is an indication for drug development with over 10 pipeline drugs currently active. According to GlobalData, preregistered drugs for Pancreatic Tumor have a 100% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Pancreatic Tumor compared to historical benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Pancreatic Tumor overview
Pancreatic cancer refers to the carcinoma arising from the pancreatic duct cells. Small changes in the cellular DNA result in uncontrolled multiplication and accumulation of cells into a tumor. Signs and symptoms of the most common form of pancreatic cancer may include yellow skin, abdominal or back pain, unexplained weight loss, light-colored stools, dark urine, and loss of appetite. Surgical resection is the only current option for a cure, but only 20% of pancreatic cancer is surgically resectable at the time of diagnosis.
For a complete picture of PTSR and LoA scores for drugs in Pancreatic Tumor, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.